Case ID: f-appx_412/html/0297-01.html
Source: Caselaw Access Project
Author: {"author": "PER CURIAM.", "license": "Public Domain", "url": "https://static.case.law/"}
Date Created: 2024-08-24T03:29:51.129683

In re OMEPRAZOLE PATENT LITIGATION. Astrazeneca AB, Aktiebolaget Hassle, KBI-E, Inc., KBI, Inc., and Astraz-eneca LP, Plaintiffs-Appellees, v. Mylan Laboratories Inc. (now known as Mylan Inc.), Mylan Pharmaceuticals Inc., Laboratorios Dr. Esteve, S.A. and Esteve Química, S.A., Defendants-Appellants.
    No. 2010-1414.
    United States Court of Appeals, Federal Circuit.
    March 8, 2011.
    Errol B. Taylor, Milbank, Tweed, Had-ley & McCloy LLP, of New York, NY, argued for plaintiffs-appellees. With him on the brief were Fredrick M. Zullow, John M. Griem, Jr., and Christopher J. Gaspar.
    James H. Wallace, Jr., Wiley Rein, LLP, of Washington, DC, argued for defendants-appellants. With him on the brief were Mark A. Pacella and Brian H. Pandya.
    Before RADER, Chief Judge, MOORE and O’MALLEY, Circuit Judges.
   JUDGMENT

PER CURIAM.

This Cause having been heard and considered, it is

Ordered and Adjudged:

AFFIRMED. See Fed. Cir. R. 36.